vs
FIRST INDUSTRIAL REALTY TRUST INC（FR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是FIRST INDUSTRIAL REALTY TRUST INC的1.1倍（$219.9M vs $194.8M），FIRST INDUSTRIAL REALTY TRUST INC净利率更高（75.9% vs -1.0%，领先76.9%），FIRST INDUSTRIAL REALTY TRUST INC同比增速更快（10.0% vs 2.0%），过去两年FIRST INDUSTRIAL REALTY TRUST INC的营收复合增速更高（8.9% vs 8.0%）
该企业是一家房地产投资信托机构，主要投资华盛顿大都会区郊区的工业地产与商务园区类资产，拥有成熟的不动产投资运营经验，于2017年被政府物业收入信托正式收购。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FR vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$194.8M
营收增速更快
FR
高出8.1%
2.0%
净利率更高
FR
高出76.9%
-1.0%
两年增速更快
FR
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $219.9M |
| 净利润 | $147.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 75.9% | -1.0% |
| 营收同比 | 10.0% | 2.0% |
| 净利润同比 | 179.7% | 92.4% |
| 每股收益（稀释后） | $1.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FROFIX
| Q1 26 | $194.8M | — | ||
| Q4 25 | $188.4M | $219.9M | ||
| Q3 25 | $181.4M | $205.6M | ||
| Q2 25 | $180.2M | $203.1M | ||
| Q1 25 | $177.1M | $193.6M | ||
| Q4 24 | $175.6M | $215.7M | ||
| Q3 24 | $167.6M | $196.6M | ||
| Q2 24 | $164.1M | $198.6M |
净利润FROFIX
| Q1 26 | $147.9M | — | ||
| Q4 25 | $78.8M | $-2.2M | ||
| Q3 25 | $65.3M | $-22.8M | ||
| Q2 25 | $55.2M | $-14.1M | ||
| Q1 25 | $48.1M | $-53.1M | ||
| Q4 24 | $68.4M | $-29.1M | ||
| Q3 24 | $99.4M | $-27.4M | ||
| Q2 24 | $51.3M | $-33.4M |
毛利率FROFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率FROFIX
| Q1 26 | — | — | ||
| Q4 25 | 34.6% | 0.2% | ||
| Q3 25 | 37.0% | -8.3% | ||
| Q2 25 | 31.7% | -7.9% | ||
| Q1 25 | 31.2% | -25.2% | ||
| Q4 24 | 40.1% | -5.3% | ||
| Q3 24 | 62.6% | -9.6% | ||
| Q2 24 | 31.8% | -12.5% |
净利率FROFIX
| Q1 26 | 75.9% | — | ||
| Q4 25 | 41.8% | -1.0% | ||
| Q3 25 | 36.0% | -11.1% | ||
| Q2 25 | 30.6% | -6.9% | ||
| Q1 25 | 27.2% | -27.4% | ||
| Q4 24 | 39.0% | -13.5% | ||
| Q3 24 | 59.3% | -13.9% | ||
| Q2 24 | 31.3% | -16.8% |
每股收益（稀释后）FROFIX
| Q1 26 | $1.08 | — | ||
| Q4 25 | $0.60 | $-0.05 | ||
| Q3 25 | $0.49 | $-0.57 | ||
| Q2 25 | $0.42 | $-0.36 | ||
| Q1 25 | $0.36 | $-1.35 | ||
| Q4 24 | $0.51 | $-0.76 | ||
| Q3 24 | $0.75 | $-0.71 | ||
| Q2 24 | $0.39 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $450.0M |
| 总资产 | $5.8B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FROFIX
| Q1 26 | — | — | ||
| Q4 25 | $78.0M | $82.0M | ||
| Q3 25 | $33.5M | $62.9M | ||
| Q2 25 | $34.9M | $65.6M | ||
| Q1 25 | $35.7M | $58.0M | ||
| Q4 24 | $44.5M | $83.2M | ||
| Q3 24 | $47.1M | $30.1M | ||
| Q2 24 | $38.5M | $26.4M |
总债务FROFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益FROFIX
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.7B | $450.0M | ||
| Q3 25 | $2.7B | $442.5M | ||
| Q2 25 | $2.6B | $458.3M | ||
| Q1 25 | $2.7B | $458.3M | ||
| Q4 24 | $2.7B | $503.1M | ||
| Q3 24 | $2.6B | $525.9M | ||
| Q2 24 | $2.6B | $546.0M |
总资产FROFIX
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.7B | $850.6M | ||
| Q3 25 | $5.5B | $832.6M | ||
| Q2 25 | $5.5B | $837.2M | ||
| Q1 25 | $5.4B | $823.1M | ||
| Q4 24 | $5.3B | $893.3M | ||
| Q3 24 | $5.2B | $867.9M | ||
| Q2 24 | $5.2B | $882.0M |
负债/权益比FROFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FROFIX
| Q1 26 | — | — | ||
| Q4 25 | $461.3M | $27.7M | ||
| Q3 25 | $124.6M | $12.4M | ||
| Q2 25 | $126.1M | $11.6M | ||
| Q1 25 | $88.6M | $-18.4M | ||
| Q4 24 | $352.5M | $23.7M | ||
| Q3 24 | $105.5M | $11.7M | ||
| Q2 24 | $107.7M | $9.0M |
自由现金流FROFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率FROFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度FROFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率FROFIX
| Q1 26 | — | — | ||
| Q4 25 | 5.85× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 2.28× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 5.15× | — | ||
| Q3 24 | 1.06× | — | ||
| Q2 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FR
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
